Adjusted Difference of Differences for the Intervention and Control Groups for Each Quality Indicator Based on Medical Record Abstractions
| Intervention Group (n = 101) | Control Group (n = 64) | |||||
|---|---|---|---|---|---|---|
| Quality Indicator | Final Passing (%) | Change From Initial (%) | Final Passing (%) | Change From Initial (%) | Adjusted Differences of Differences | AdjustedPValue for Differences of Differences |
| * Significant at P <.05. | ||||||
| † Significant at P <.01. | ||||||
| 1. All patients should have a β2-agonist prescribed for symptomatic relief | 83 | 2 | 89 | 6 | −4 | .68 |
| 2. Peak expiratory flow rate (or spirometry) should be measured in all patients at least annually | 28 | 21 | 14 | 0 | 17 | .03* |
| 3. No β-blocker should be prescribed for patients with diagnosed asthma | 92 | −2 | 92 | −2 | 0 | .94 |
| 4. All patients should have a written action plan in the medical record based on changes in symptoms or peak flow measurements | 27 | 26 | 0 | 0 | 26 | <.0001† |
| 5. Patients with asthma should have at least 2 routine planned follow-up visits for asthma annually | 77 | −8 | 91 | 2 | −7 | .41 |
| 6. Patients should be educated by physician in self-management of asthma | 37 | 15 | 10 | −3 | 15 | .07 |
| 7. Patients prescribed inhaled medications should be instructed in use of metered- dose inhalers | 22 | 15 | 7 | 7 | 13 | .04 |
| 8. Evidence of collaborative goal setting between patient and clinician and lay educator should be recorded at least annually | 7 | 7 | 0 | 0 | 7 | .03* |
| 9. Overall asthma process of care summary score | 46 | 10 | 38 | 1 | 8 | .003† |